Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
338 - Can you advise if published, qualitative studies are acceptable for patient preference claims under the new Code?
-
I presume you are asking whether it is acceptable to use a survey to assess patient preferences. If I am far off of your intended meaning give me a call. The code change had no impact on this topic. As per before the code change, we can consider this type of presentation when the survey was conducted by a third party receiving unrestricted funding from the sponsor (e.g. sponsor had no influence on the design, the selection of participants, creation of the survey instrument, implementation of the survey, and the analysis of the results). Preference claims must be based on statistically significant results and limited to non-therapeutic aspects of treatment (e.g. "preferred the taste of... " or "preferred the nozzle length of..."). Open claims of "preferred drug X" (i.e. without explicit limitation to non-therapeutic aspects) are not accepted from surveys. Claims of "preferred the efficacy [or safety] of..." are also not accepted based on surveys. Again, call me of this is not what you were looking for.
